58.59
+0.68(+1.17%)
Currency In USD
| Previous Close | 57.91 |
| Open | 58.5 |
| Day High | 59.19 |
| Day Low | 58.03 |
| 52-Week High | 70.81 |
| 52-Week Low | 52.5 |
| Volume | 185,138 |
| Average Volume | 244,956 |
| Market Cap | 1.23B |
| PE | -124.66 |
| EPS | -0.47 |
| Moving Average 50 Days | 56.62 |
| Moving Average 200 Days | 60.31 |
| Change | 0.68 |
If you invested $1000 in ANI Pharmaceuticals, Inc. (ANIP) 10 years ago, it would be worth $1,029.34 as of February 05, 2025 at a share price of $58.59. Whereas If you bought $1000 worth of ANI Pharmaceuticals, Inc. (ANIP) shares 5 years ago, it would be worth $929.41 as of February 05, 2025 at a share price of $58.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference
GlobeNewswire Inc.
Jan 28, 2025 9:30 PM GMT
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
GlobeNewswire Inc.
Jan 13, 2025 11:50 AM GMT
For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024Rare Disease Segment performed in line with expectations, with P
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity
GlobeNewswire Inc.
Jan 02, 2025 11:50 AM GMT
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application